Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178125 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,858
- Enrollment target
NCT01178125 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 2,858 participants.
The verdict
NCT01178125, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,858 participants
- Enrollment target
Study Summary
This is an open-label, single treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-102. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a daily diary.
Interventions
- DRUG DR-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,858 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178125
The ClinicalTrials.gov registry entry for NCT01178125 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,858 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DR-102 is the first listed.
NCT01178125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01178125 about?
NCT01178125 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy". This is an open-label, single treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-102. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a daily diary.
What is the current status of trial NCT01178125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,858 participants. The study started on 2010-08. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01178125?
The interventions under investigation include: DR-102 (DRUG).
Who is sponsoring clinical trial NCT01178125?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.